Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

Base on this PR, I believe BPs wanted to see both antibiotic and anti-inflammatory properties proven first before making an offer.

“What must be stressed is that Brilacidin is a mature, later-stage drug candidate with platform potential. It took the recent completion of two Phase 2 trials, in IBD and OM, to further validate the exceptional results achieved from our Phase 2b study in ABSSSI. These recent data, taken in aggregate, are what various actively engaged pharmaceutical companies have desired from us for some time—and they are what triggered a newfound flurry of inbound partnership discussions at the San Francisco conferences," commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals.

http://www.ipharminc.com/press-release/2018/1/16/innovation-pharmaceuticals-presents-at-2018-biotech-conference-oral-mucositis-drug-candidate-garners-exceptional-interest-after-successful-phase-2-trial

It makes sense. If a company claims they have a new car that can also float and fly. The floating part is proven but the flying part is not. Would you make an offer before the flying part is proven?